NYMOX PHARMACEUTICAL CORP
NYMXF · OTCMCIK 1018735fmd_0YFJA6FKYS5TZS6H3PZK18Z0BNManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 33 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Gross profit | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Research and development | 9 | 7 | 8 | 7 | 7 | 8 | 7 | 4 | 4 | 3 |
| Selling, general and administrative | 12 | 6 | 5 | 4 | 6 | 4 | 6 | 3 | 4 | 1 |
| Operating income | (18) | (13) | (13) | (11) | (13) | (12) | (13) | (7) | (8) | (4) |
| Interest expense | (0) | (0) | (0) | 0 | 0 | (0) | 0 | 0 | 0 | 0 |
| Income before taxes | (18) | (13) | (13) | (11) | (0) | (12) | (13) | (7) | (9) | (4) |
| Income tax expense | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | (11) | (0) | (12) | (13) | (7) | (9) | (4) |
| Net income | (18) | (13) | (13) | (11) | (13) | (12) | (13) | (7) | (9) | (4) |